{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:16:34Z","timestamp":1762607794244},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>This study aimed to evaluate in vitro susceptibility to ceftobiprole of clinical strains identified from prosthetic joint infections (PJIs) compared to that of the associations currently recommended for post-operative empirical antibiotic therapy (PEAT) (vancomycin with either cefepime, third-generation cephalosporin or piperacillin\u2013tazobactam).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We performed a 1-year retrospective study on all the surgical procedures performed in our hospital for PJI. Susceptibility profiles of all the strains cultured from surgical samples were reviewed to compare ceftobiprole to current used associations.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>During the study period (from January 2018 to December 2018), we identified 106 patients managed for PJI and a total of 216 surgical interventions. One hundred-fifty strains were identified from intraoperative samples, excluding redundant strains. <jats:italic>Staphylococcus<\/jats:italic> spp. represented 52.7% of all strains and Enterobacteriales 13.3%. Twenty-three patients had polymicrobial infection (22%). Among 149 surgical procedures with positive culture results, ceftobiprole covered the bacterial strains in 138 (92.6%) cases. In comparison, this percentage was 94.6% for vancomycin plus cefepime (p\u2009=\u20090.64), 92.6% for vancomycin plus a third-generation cephalosporin in 138 cases (p\u2009=\u20091) and 94.6% for vancomycin plus piperacillin\u2013tazobactam) (p\u2009=\u20090.64).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Based on antimicrobial susceptibility testing, our results suggest that ceftobiprole could be an interesting option for PEAT in PJIs, allowing the use of a single agent.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12941-020-00351-5","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T06:02:42Z","timestamp":1584770562000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections"],"prefix":"10.1186","volume":"19","author":[{"given":"Claire","family":"Duployez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Wallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Migaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Senneville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Loiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,21]]},"reference":[{"issue":"11","key":"351_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1302\/0301-620x.95b11.33135","volume":"95-B","author":"J Parvizi","year":"2013","unstructured":"Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus on periprosthetic joint infection. Bone Joint J. 2013;95-B(11):1450\u20132. https:\/\/doi.org\/10.1302\/0301-620x.95b11.33135.","journal-title":"Bone Joint J"},{"issue":"1","key":"351_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cis803","volume":"56","author":"DR Osmon","year":"2013","unstructured":"Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR, Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1\u201325. https:\/\/doi.org\/10.1093\/cid\/cis803.","journal-title":"Clin Infect Dis"},{"key":"351_CR3","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Recommandations de bonne pratique\u2014Proth\u00e8se de hanche ou de genou: diagnostic et prise en charge de l\u2019infection dans le mois suivant l\u2019implantation. 2014. www.has-sante.fr."},{"issue":"16","key":"351_CR4","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMra040181","volume":"351","author":"W Zimmerli","year":"2004","unstructured":"Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645\u201354.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"351_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1469-0691.2006.01404.x","volume":"12","author":"HF Chambers","year":"2006","unstructured":"Chambers HF. Ceftobiprole: in vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect. 2006;12(Suppl 2):17\u201322 (Review).","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"351_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2008.12.012","volume":"34","author":"A Barbour","year":"2009","unstructured":"Barbour A, Schmidt S, Rand KH, Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2009;34(1):1\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.12.012.","journal-title":"Int J Antimicrob Agents"},{"key":"351_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jgar.2018.01.022","volume":"13","author":"C Isnard","year":"2018","unstructured":"Isnard C, Dhalluin A, Malandain D, Bruey Q, Auzou M, Michon J, Giard JC, Gu\u00e9rin F, Cattoir V. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections. J Glob Antimicrob Resist. 2018;13:221\u20135. https:\/\/doi.org\/10.1016\/j.jgar.2018.01.022.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"351_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1469-0691.2008.02663.x","volume":"15","author":"B Hellmark","year":"2009","unstructured":"Hellmark B, Unemo M, Nilsdotter-Augustinsson A, S\u00f6derquist B. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect. 2009;15(3):238\u201344. https:\/\/doi.org\/10.1111\/j.1469-0691.2008.02663.x.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"351_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.diagmicrobio.2007.02.010","volume":"58","author":"MS Rouse","year":"2007","unstructured":"Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis. 2007;58(3):363\u20135.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"351_CR10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s10096-018-3295-6","volume":"37","author":"AS Henriksen","year":"2018","unstructured":"Henriksen AS, Smart J, Hamed K. Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013\u20132015. Eur J Clin Microbiol Infect Dis. 2018;37(9):1653\u20139. https:\/\/doi.org\/10.1007\/s10096-018-3295-6.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"351_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijantimicag.2013.11.005","volume":"43","author":"DJ Farrell","year":"2014","unstructured":"Farrell DJ, Flamm RK, Sader HS, Jones RN. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. Int J Antimicrob Agents. 2014;43(4):323\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.11.005.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"351_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1128\/AAC.00886-09","volume":"54","author":"P Tattevin","year":"2010","unstructured":"Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(2):610\u20133. https:\/\/doi.org\/10.1128\/AAC.00886-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"351_CR13","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1128\/AAC.02465-14","volume":"58","author":"DJ Farrell","year":"2014","unstructured":"Farrell DJ, Flamm RK, Sader HS, Jones RN. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrob Agents Chemother. 2014;58(7):3882\u20138. https:\/\/doi.org\/10.1128\/AAC.02465-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"351_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2017.12.020","volume":"91","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS. Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). Diagn Microbiol Infect Dis. 2018;91(1):77\u201384. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.12.020.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"351_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijantimicag.2013.09.013","volume":"43","author":"D Abbanat","year":"2014","unstructured":"Abbanat D, Shang W, Amsler K, Santoro C, Baum E, Crespo-Carbone S, Lynch AS. Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays. Int J Antimicrob Agents. 2014;43(1):32\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.09.013.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"351_CR16","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1128\/AAC.00638-07","volume":"52","author":"LY Yin","year":"2008","unstructured":"Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(5):1618\u201322. https:\/\/doi.org\/10.1128\/AAC.00638-07.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-00351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12941-020-00351-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-00351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:06:20Z","timestamp":1616285180000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-020-00351-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,21]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1186\/s12941-020-00351-5","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,21]]},"assertion":[{"value":"5 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}